ATP. a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ATP Founds New Center for CRISPR Target Discovery in Collaboration with Innovative Genomics Institute (IGI) and Jennifer Doudna
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome